{"schema_version":"secwatch.filing_event.v1","accession":"0000064803-24-000015","form_type":"8-K","ticker":"CVS","cik":"0000064803","company_name":"CVS HEALTH Corp","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.688959+00:00","generated_at":"2026-06-03T03:26:54.101913+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CVS Health Q1 GAAP EPS $0.88 vs $1.65; FY2024 guidance slashed on Medicare pressure","bullets":["Q1 revenues rose 3.7% to $88.4B; GAAP diluted EPS $0.88 vs $1.65; adjusted EPS $1.31 vs $2.20.","Operating income fell to $2.3B from $3.4B; Health Care Benefits segment pressured by Medicare utilization.","FY2024 guidance cut: GAAP EPS at least $5.64 (from $7.06); Adj EPS at least $7.00 (from $8.30).","Q1 cash flow from operations $4.9B; FY guidance reduced to at least $10.5B from $12.0B.","CEO cites Medicare Advantage challenges; expects elevated cost trends to persist through 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000064803-24-000015","json":"https://secwatch.observer/filing/0000064803-24-000015.json","markdown":"https://secwatch.observer/filing/0000064803-24-000015.md","text":"https://secwatch.observer/filing/0000064803-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/64803/000006480324000015/0000064803-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64803/000006480324000015/cvs-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:26:54.101913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f4e56b90f73c06f42f945605a78fb27166e9800","claim":"CVS HEALTH Corp reported full-year 2024 results: EPS Revised GAAP diluted EPS guidance to at least $5.64 from at least $7.06. Guidance lowered.","evidence_excerpt":"Revised GAAP diluted EPS guidance to at least $5.64 from at least $7.06","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/64803/000006480324000015/0000064803-24-000015-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2024"},{"label":"EPS","value":"Revised GAAP diluted EPS guidance to at least $5.64 from at least $7.06"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"43d38ed9af97794610c162217d20a47c636a898c","claim":"CVS HEALTH Corp reported the three months ended March 31, 2024 results: revenue $88,437, EPS $0.88.","evidence_excerpt":"results for the three months ended March 31, 2024. Financial Results Summary Three Months Ended March 31, In millions, except per share amounts 2024 2023 Change Total revenues $ 88,437 $ 85,278 $ 3,159 Operating income 2,271 3,446 (1,175) Adjusted operating income (1) 2,957 4,370 (1,413) Diluted earnings per share $ 0.88 $ 1.65 $ (0.77) Adjusted EPS (2) $ 1.31 $","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/64803/000006480324000015/0000064803-24-000015-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$88,437"},{"label":"EPS","value":"$0.88"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}